Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Recruiting · NCT05886036 · Registry updated 2026-08-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial | Nodular Lymphocyte Predominant B-Cell Lymphoma; Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma; Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma | Recruiting | Phase 2 | 2026-08-31 | NCT05886036 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
37 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.